Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.45 |
| ▸ | RPS6KA1 | Q15418 | 4/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885967 | 0.87 | TP53 (0.58) | TP53GPBAR1ROCK1RPS6KA1RPS6KB1 | |
| SCHEMBL4322189 | 0.85 | TP53 (0.69) | TP53GPBAR1SMN1; SMN2IDO1TSHR | |
| SCHEMBL3883649 | 0.83 | GPBAR1 (0.69) | TP53GPBAR1SMN1; SMN2TSHR | |
| SCHEMBL3895930 | 0.81 | GPBAR1 (0.67) | TP53GPBAR1ROCK1RPS6KA1RPS6KB1 | |
| SCHEMBL4322087 | 0.78 | MAPK1 (0.41) | GPBAR1SMN1; SMN2 | |
| SCHEMBL3898543 | 0.78 | TP53 (0.67) | TP53GPBAR1SMN1; SMN2TSHRPKM | |
| SCHEMBL3885823 | 0.76 | ROCK1 (0.79) | ROCK1RPS6KA1RPS6KB1ROCK2 | |
| SCHEMBL3886366 | 0.76 | ROCK1 (0.81) | TP53ROCK1RPS6KA1RPS6KB1ROCK2 | |
| SCHEMBL3885355 | 0.75 | ROCK1 (0.68) | TP53ROCK1RPS6KA1RPS6KB1ROCK2 | |
| SCHEMBL3896684 | 0.74 | ROCK1 (0.57) | TP53GPBAR1ROCK1RPS6KA1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1718638-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1718638-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082890-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058384-A1 | Novel Compounds | ARHGDIB, TNK2, ROCK2 | TP53 3036/4885GPBAR1 2826/4885ROCK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.